Growth Metrics

Alx Oncology Holdings (ALXO) Total Non-Current Liabilities (2019 - 2026)

Alx Oncology Holdings recorded quarterly Total Non-Current Liabilities of $23.5 million in Q1 2026, down 19.3% quarter-over-quarter from $29.1 million in Q4 2025, and down 12.98% year-over-year from $27.0 million in Q1 2025.

Alx Oncology Holdings' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $23.5 million for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities fell 12.98% year-over-year to $23.5 million; the TTM figure through Mar 2026 stood at $23.5 million (down 12.98% YoY), while the FY2025 annual figure was $29.1 million, up 3.99% from the prior year.
  • Total Non-Current Liabilities came in at $23.5 million for Q1 2026 at Alx Oncology Holdings, down from $29.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $48.2 million in Q2 2024 to a low of $15.3 million in Q1 2022.
  • A 5-year average of $32.4 million and a median of $29.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities soared 146.58% in 2022 and tumbled 46.4% in 2025, its largest moves.
  • Alx Oncology Holdings' Total Non-Current Liabilities stood at $37.7 million in 2022, then gained by 21.02% to $45.6 million in 2023, then tumbled by 38.72% to $28.0 million in 2024, then rose by 3.99% to $29.1 million in 2025, then declined by 19.3% to $23.5 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $23.5 million, $29.1 million, and $33.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 11.03 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 42,980.09
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 95.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 110.28 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.87 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 7.32 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 4.05 Bn
10 Alx Oncology Holdings 189.80 Mn 49.48 Mn - 23.47 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 23.47 Mn
Dec 31, 2025 29.09 Mn
Sep 30, 2025 33.49 Mn
Jun 30, 2025 25.85 Mn
Mar 31, 2025 26.97 Mn
Dec 31, 2024 27.97 Mn
Sep 30, 2024 42.18 Mn
Jun 30, 2024 48.22 Mn
Mar 31, 2024 41.93 Mn
Dec 31, 2023 45.64 Mn
Sep 30, 2023 44.72 Mn
Jun 30, 2023 27.08 Mn
Mar 31, 2023 31.34 Mn
Dec 31, 2022 37.71 Mn
Sep 30, 2022 25.24 Mn
Jun 30, 2022 23.95 Mn
Mar 31, 2022 15.31 Mn
Dec 31, 2021 15.30 Mn
Sep 30, 2021 12.49 Mn
Jun 30, 2021 13.98 Mn
Mar 31, 2021 14.13 Mn
Dec 31, 2020 6.20 Mn
Sep 30, 2020 10.39 Mn
Jun 30, 2020 11.65 Mn
Dec 31, 2019 10.41 Mn